

ASX ANNOUNCEMENT
29 April 2013

Bionomics Presents Update on BNC101 at Leading US Antibody Conference

Bionomics Limited (ASX: BNO) (ADR: BMICY) today announced that Dr Christopher Reyes, its Vice President of Research and Development Biologics, will provide an update on the BNC101 LGR5 cancer program and its CSC Rx Discovery™ platform at the 2013 PEGS “Promising New Targets – Oncology Stream” meeting in Boston, MA, USA.

BNC101 entered Bionomics’ pipeline as a result of Bionomics’ acquisition of San Diego-based Eclipse Therapeutics. Following the completion of IND enabling studies, BNC101 is anticipated to enter clinical trials in 2014.

BNC101, which is a humanized monoclonal antibody, has demonstrated functional activity against Cancer Stem Cells (CSCs) from primary colorectal cancer (CRC) patient samples with multiple underlying gene mutations. Preclinical studies have demonstrated that BNC101 significantly reduces CSC frequency and prevents tumour re-growth in long term studies. BNC101 increases survival and inhibits weight loss in a cachectic CRC tumour model. To date BNC101 has not shown evidence of toxicity in a preliminary safety analysis.

LGR5 is a high value cancer stem cell marker targeted by BNC101.

Lineage tracing experiments performed in Professor Hans Clevers’ laboratory at the Hubrecht Institute, Netherlands, provide direct, functional evidence that LGR5 marks cancer stem cells in mouse intestinal adenomas. LGR5 is highly overexpressed in colorectal (CRC), as well as esophageal, stomach, liver, and pancreatic cancer and high expression of LGR5 correlates with significantly increased likelihood of relapse in colorectal cancer.

Data generated by both Bionomics and independent academic investigators indicate that LGR5 is a functional CSC target in CRC and other tumours, including metastatic triple-negative breast cancer.

The clinical strategy for BNC101 will target solid tumours expressing LGR5 where there is a high rate of relapse. Colorectal cancer and pancreatic cancer have been chosen as initial priority indications.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule and antibody product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.